NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC

This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.

Trial Details

NCT ID
NCT07295262
Phase
EARLY_PHASE1
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • ICG-Cisplatin Nanoprobe (NIR-II NanoM)
  • Fluorescence-guided Hepatectomy
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Age 18-75 years.
  • First diagnosis of Hepatocellular Carcinoma (HCC) (non-recurrent).
  • Single tumor with diameter ≤ 5 cm.
  • Assessed as resectable by more than 2 senior liver surgeons (experience \>10 years, \>500 hepatectomies).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →